Save Ceftolozane/Tazobactam for Resistant E. coli or Pseudomonas
Reps will be promoting a new IV anti-infective, ceftolozane/tazobactam (Zerbaxa).
It's approved for complicated UTIs (cUTIs) and intra-abdominal infections (cIAIs) in adults. And higher doses are also being studied for ventilator-associated pneumonia.
Ceftolozane/tazobactam primarily covers gram-negative bacteria...including Pseudomonas and ESBL-producing Enterobacteriaceae.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber's Letter includes:
- 12 issues every year, with brief articles about new meds and guidelines
- 48+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive
Already a subscriber? Log in
Volume pricing available. Get a quote